Maladies du Rein

Nom du produit

Endostatin mouse/rat

Cat. noBI-20742MR
Gamme0 – 32 nmol/l
Sensibilité0.5 nmol/l (STD2 1 nmol/l)
Durée d'incubation2 h / 30 min
Volume échantillon5 μl
Echantillon

Serum, plasma

Précautions

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 3 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Valeurs de référence

Mouse sera C57BL6JOlaHsd, 12 weeks (n=11): 6.7 ± 0.8 nmol/l
Wildtype normal mice sera, 12 weeks, male (n=10): 5.4 ± 1.2 nmol/l
Wildtype normal rat sera, 12 weeks, male (n=8): 2.5 ± 0.4 nmol/l

Espèces

Mouse, rat

Tests96
MéthodeELISA
Intérêt clinique

Intended use:

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs http://www.uniprot.org/uniprot/P39060). The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins. In animal studies, renal Endostatin expression preceded deteriorating kidney function and induced renal fibrosis in aging mice. In humans, Endostatin is expressed during the progression of renal fibrosis in tubular cells of injured tissue .In renal micro-vascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation.
Thus endostatin may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial- and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome. In a cohort of critically ill patients, plasma endostatin improved AKI prediction based on clinical risk factors. Endostatin has evolved as a molecular target and is currently under investigation in clinical trials.

Intended applications:

Micro-vascular injury
Chronic kidney disease
Atherosclerosis
Ischemia
Sepsis
Preeclampsia

Informations utiles

Retour à l'index